Heng Zhou

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also affiliated with Merck Biopharma Co., Ltd. (Japan), Decision Sciences (United States), Yangzhou University

MathematicsDecision SciencesEconomics, Econometrics and FinanceMedicineComputer Science

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “794 Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors”.

794 Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors

(2020)10.1136/jitc-2020-sitc2020.0794

N/A

0DataRank · unranked

4 citations

Caroline Gaudy‐Marqueste, Martin Wermke, Antoîne Italiano, Emanuela Romano, Aurélien Marabelle +7 more

A Generalized Model-Free Framework for Dose Optimization in Multiple-Dose Randomized Early-Phase Clinical Trials

Statistics in Biosciences(2025)10.1007/s12561-025-09481-w

N/A

0DataRank · unranked

0 citations

Fang Liu, Qing Zhao, Yixin Ren, Heng Zhou, Yingjie Qiu